U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06991491) titled 'Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)' on May 14.
Brief Summary: The aim of this study is to explore the efficacy and safety of a new combination regimen of GnP regimen, SBRT and the anti-PD-1/VEGF bis-antibody, Ivonescimab, in patients with recurrent metastatic advanced pancreatic cancer. The efficacy predictive biomarkers of this combination regimen will be further explored through information such as spatial analysis of the tumor immune microenvironment.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
COMBINATION_PRODUCT: GnP...